Skip to content
Sign in
SWC 2026 FinalistGrand Final: Lunch Block

Byonyks

FDA-cleared low-cost automated peritoneal dialysis cycler, built in a DRAP-approved Pakistani factory, preparing first US patients.

Itasca, IL (production in Lahore, Pakistan), United States, North AmericaMedTech & devices, At-home peritoneal dialysis
Stage
SeedNo documented AI
Product
PilotPilots / LOIs
Funding raised
$9Mdisclosed
Founded
20197 years ago
Founders
4Farrukh, Michael…
Global score
5.5Grade CRank 25 of 151

Overview

Byonyks is developing an affordable, portable “bloodless” dialysis system for home treatment of kidney failure, with a factory in Pakistan.

Traction

Pilots / LOIs

X-1 APD cycler and DS-1 set: FDA 510(k) clearance K243371 (decision of 16 May 2025, class II); BALANZ clinical study cited; DRAP-approved factory in Pakistan; in 2026 the company is setting up its US infrastructure and plans to start its first US patients (no confirmed sales).

Market

Peritoneal dialysis

Kidney failure is rising with diabetes and hypertension, and in-centre haemodialysis is expensive and unavailable in much of the developing world. Home peritoneal dialysis is cheaper and gives patients autonomy, but cyclers are expensive and dominated by a few incumbents. Buyers are dialysis providers, nephrology clinics, hospitals and payers; in emerging markets, governments and insurers. FDA clearance plus low-cost manufacturing positions Byonyks for both the US and price-sensitive markets.

Addressable market

2025
$10.1B
2030Not estimated
+5.8% a year

Peritoneal dialysis: ~$10bn in 2025 ($9.58bn in 2024 to $12.7bn in 2029, CAGR 5.8%, MarketsandMarkets).

Customers

Dialysis providers, nephrology clinics, hospitals, home-dialysis patients

Who signs the cheque

Dialysis provider procurement, payers (US CMS), governments and insurers in emerging markets

Geographies

  • United States
  • Pakistan

Drivers

  • Rising chronic kidney disease prevalence
  • Policy push toward home dialysis
  • Cost pressure on dialysis budgets

Headwinds

  • Competition from dialysis leaders
  • Commercialisation still to be proven
  • Consumables supply chain and training

Global peritoneal dialysis market from $9.58bn in 2024 to $12.7bn in 2029 (MarketsandMarkets, CAGR 5.8%), i.e. ~$10bn in 2025; range $6–19bn depending on the firm.

Scalability 5/10. FDA-cleared medical hardware with a factory in Pakistan, but distribution and reimbursement must be negotiated country by country.

Market source: barchart.com

Technology

Category

Regulated medical device (home dialysis)

No documented AI

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

pilot

How it works

The X-1 automated peritoneal dialysis cycler and DS-1 set deliver ‘bloodless’ home dialysis. The system has FDA 510(k) clearance K243371 (class II).

Moat

Strong: FDA clearance and a regulator-approved low-cost factory are hard to replicate quickly.

Differentiation

Affordable, portable cycler versus incumbent premium devices.

Integration points

  • Remote patient monitoring / telehealth platforms
  • IoT device management for connected cyclers
  • Nephrology EHRs

Depends on

  • Consumables supply
  • Clinical training and support
  • Reimbursement and provider contracts

Use of AI

No use of AI mentioned

Product in detail

Byonyks X1 automated peritoneal dialysis cycler, which has obtained FDA 510(k) clearance.

Business

Model
Device and consumables sales (razor/razor-blade), possibly service contracts.
Revenue logic
Device plus recurring disposable sets per treatment (pricing not disclosed).
Go-to-market
US launch with first patients in 2026; manufacturing in Pakistan for cost advantage.

Next milestones

  1. First US patients and provider contract
  2. Remote-monitoring offering
  3. Series A

Key risks

  • Incumbent competition
  • Commercial execution
  • Funding (USD 9M note in 2023)

Opportunities

4 found in the network

Concrete moves for Byonyks inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Market entry 1
  • Co-development 1
  • Investors 2

Market entry1

A local partner where they want to go

Pair home PD with TIBOK’s doctor-led remote monitoring in Africa and the Indian Ocean

Home PD needs remote follow-up by nephrologists and nurses, which is scarce in emerging markets; TIBOK provides doctor-led chronic care monitored by Eva, connected devices and national proposals to governments. A bundled ‘device + remote care’ offer would make Byonyks' low-cost cycler deployable in countries without dialysis centres.

25%confidence

Evidence from the records

  • “affordable, portable “bloodless” dialysis system for home treatment of kidney failure, with a factory in Pakistan”
  • “chronic care led by the doctor and monitored by Eva”
  • “National proposals submitted to governments in Africa and the Indian Ocean.”
If it works
A joint proposal for a home-dialysis pilot in Mauritius or Madagascar.
First step
Organise a call between both CEOs to scope device data feeds into TIBOK's chronic-care pathway.

Co-development1

An integration or joint product

Connect and update the X-1 fleet remotely with Qbee

A fleet of home cyclers needs secure remote monitoring and OTA updates; Qbee provides exactly that for Linux embedded devices. Using an existing control plane avoids building one and supports post-market surveillance.

20%confidence

Evidence from the records

  • “X-1 APD cycler and DS-1 set: FDA 510(k) clearance K243371”
  • “configuration management, OTA updates, automation, monitoring and secure remote access to embedded devices”
If it works
A connectivity layer for US launch, provided the X-1 runs embedded Linux.
First step
Check X-1's embedded OS and request Qbee's medical-device security documentation.

Investors2

A fund whose thesis fits

Approach Sands Capital for a MedTech Series A

Sands Capital invests Series A and later in MedTech and life sciences globally and is reported as an investor in network member PolyJoule. Byonyks' FDA clearance makes it a Series A candidate once first US patients are treated.

20%confidence

Evidence from the records

  • “Sands Capital Ventures and others (according to aggregators)”
  • “FDA 510(k) clearance”
If it works
A Series A lead to fund US commercialisation.
First step
Ask PolyJoule's team for an intro to Sands Capital Ventures.

Pitch MEVP on the Pakistan manufacturing and MENA angle

MEVP invests Series A+ in HealthTech across MENA and Pakistan; Byonyks' Pakistani factory and affordable positioning fit its regional and ESG thesis.

20%confidence

Evidence from the records

  • “Early- and growth-stage tech companies in MENA, with an ESG focus.”
  • “DRAP-approved factory in Pakistan”
If it works
A regional co-investor and MENA/Pakistan market access.
First step
Send MEVP a short memo on Pakistan and Gulf home-dialysis economics.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

Silicon Valley VC ($1.7B AUM, 200+ companies) and Startup World Cup founder, running corporate venture funds for 35+ corporates.

FDA 510(k)-cleared home dialysis system with a Pakistan factory: rare regulatory de-risking at seed and a global cost-of-care story.

50%confidence

Evidence from the records

  • “FDA 510(k) clearance K243371”
  • “At-home peritoneal dialysis”
Intro path
Startup World Cup channel.
First step
Brief Pegasus on Byonyks' US entity setup and commercialization plan.

US federal biomedical research agency funding biotech, health and medtech via SBIR and research grants (Defined Bioscience, Microvitality, Corticale).

US at-home peritoneal dialysis — kidney disease medtech.

45%confidence

Evidence from the records

  • “"MedTech & devices"”
  • “At-home peritoneal dialysis”
  • “X-1 APD cycler and DS-1 set: FDA 510(k) clearance K243371 (decision of 16 May 2025, class II)”
Intro path
Founder-to-founder intro via Corticale, Defined Bioscience, Microvitality (network portfolio company of U.S. National Institutes of Health (NIH)).
First step
Apply to NIDDK SBIR.

Life-sciences and venture arm of Sands Capital ($54B+ AUM); Pulse strategy ($1.3B) backs therapeutics, diagnostics, devices and tools.

FDA 510(k)-cleared home dialysis cycler with a manufacturing base: a de-risked medical device, though raised only at seed so far.

40%confidence

Evidence from the records

  • “FDA 510(k) clearance K243371”
  • “At-home peritoneal dialysis”
First step
Approach at Byonyks' Series A with US launch metrics.

Shenzhen life-science investor (since 2012) backing drug developers with phase 2/3 assets and device makers; backed Pleryon Therapeutics.

At-home peritoneal dialysis with FDA 510(k) clearance and a DRAP-approved factory: device maker with regulatory validation, at seed.

40%confidence

Evidence from the records

  • “At-home peritoneal dialysis”
  • “FDA 510(k) clearance K243371”
First step
Pitch an Asia manufacturing/commercial partnership.

Connecticut's state-backed strategic VC, investing in early-stage companies ($45.8M in 67 in FY2025); joined Neurosoft's $7.5M seed.

At-home peritoneal dialysis with FDA 510(k) clearance (May 2025): US medtech at commercial scale-up, seed.

35%confidence

Evidence from the records

  • “At-home peritoneal dialysis”
  • “FDA 510(k) clearance K243371”
Intro path
Neurosoft (CI portfolio, medtech peer)
First step
Evaluate a Connecticut site, then pitch CI.

US accelerator with no profile in our data; supported maternal-health medtech Lidavex.

US home dialysis at seed.

25%confidence

Evidence from the records

  • “Lidavex”
  • “At-home peritoneal dialysis”
  • “X-1 APD cycler and DS-1 set: FDA 510(k) clearance K243371 (decision of 16 May 2025, class II)”
Intro path
Founder-to-founder intro via Lidavex (network portfolio company of Octane LaunchPad).
First step
Ask Lidavex.

US investor with no profile in our data; participated in Neurosoft Bioelectronics' oversubscribed $7.5M seed.

US at-home peritoneal dialysis at seed — US medtech, different therapy area.

20%confidence

Evidence from the records

  • “Neurosoft”
  • “At-home peritoneal dialysis”
  • “X-1 APD cycler and DS-1 set: FDA 510(k) clearance K243371 (decision of 16 May 2025, class II)”
Intro path
Founder-to-founder intro via Neurosoft Bioelectronics (network portfolio company of IAG Capital Partners).
First step
Low priority.

Investment analysis

5.5C

Grade C

Rank 25 of 151

Disruption7.0/10
Business model4.0/10
Market6.0/10
Risk(lower is better)6.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

High-impact MedTech clearing the regulatory hurdle: worth following closely.

Disruption

7/10

Portable, affordable at-home peritoneal dialysis: a new approach that could change kidney care.

Business model

4/10

FDA 510(k) clearance obtained in 2025, commercialization being set up.

Market

6/10

TAM peritoneal dialysis ~$10.1bn (base 5), medium scalability 5/10 (0), international expansion: factory in Pakistan and US launch (+1) → 6/10.

Risk

6/10

Lower is better

Medium risk: FDA hurdle cleared, but commercial execution and competition (Baxter, Fresenius).

Strengths

  • FDA 510(k) clearance
  • Low-cost factory in Pakistan

Risks

  • Competition from dialysis leaders
  • Commercialization to be proven

Funding

$9M, disclosed
  1. 23 janv. 2023 (Bouncewatch) / 23 fév. 2023 (Village)

    convertible noteUSD 9M

    1 unnamed investor

Amount used in the study. $9M convertible note according to aggregators (not verified), lower bound 0.

Note. USD 9M (aggregators, not verified)

FDA clearance confirmed (K243371, 16 May 2025). Expanded leadership team on the site (Rod Kenley, Salahuddin Khan, Doug Wilkerson, Andrew King MD…) but founders not designated; no new funding round or SWC qualification found.

Team

  • Farrukh Usman

    Founder & CEO

    Master's in management (Harvard) and MS in computer science (LUMS, Lahore).

  • Michael Wollowitz

    Co-founder (founding team)

    Dialysis medical device expert, listed among the founders.

  • Eric Flachbart

    Co-founder, board member

    Medical device expert, listed among the founders.

  • Dr Frank Rudolph

    Co-founder

    Medical device expert, listed among the founders.

Sources

Wall

Wall

No posts yet